

ACT EU multi-stakeholder platform annual meeting

Amsterdam, October 22nd, 2024

Session 2 - Looking back - Overview of ACT EU delivery to date
The MSP Advisory Group and stakeholders' feedback

Russell Wheeler, EURORDIS Volunteer

ACT EU – Why Europe and why should we (patients) care?

- Patients want treatments – pure and simple.
- Many are agnostic about where the research takes place, so long as it is well regulated and thorough.
- Our main focus is safe, high quality and effective treatments delivered quickly and widely accessible.
- In theory this does not require that research takes place locally, but life is not so simple (or pure).
- While harmonisation of regulation has (mostly) improved, where the research takes place does matter, both in terms of regulatory approval and especially reimbursement and time to market.

Hopes and expectations of patients from ACT EU

- Full and frequent involvement of the Multistakeholder Partner (MSP) Advisory Board in co-creation of ACT EU
- Development of PA5 and strengthening of evidence based policymaking and regulation
- Funding to also be more efficiently targeted as a result of higher quality data more intelligently applied
- PA7 to result in fewer failed trials due to greater clarity and understanding in trial design as well as flexibility
- Greater harmonisation and understanding between regulators and payers in order to deliver faster and fairer access to treatments

Thank you

All views are my own and should not be taken
as representing the official policy of EURORDIS

russell.wheeler@eurordis.org